Talk:Sugammadex: Difference between revisions

Content deleted Content added

Inline

Revision as of 12:01, 16 September 2007

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
???	This article has not yet received a rating on the project's importance scale.

Phase III data

Any preliminary phase 3 data available for sharing? Mdw346 15:33, 7 December 2006 (UTC)MDW 07 Dec.06[reply]

Sept 16, 2007: Preliminary Phase III and updated Phase II data has been released in Europe June 9-12, 2007 at the European Society of Anaesthesiology Munich, Germany. No surprises- continued successful, effective, dose-dependent fast time to reversal of all levels of neuromuscular blockade induced by rocuronium and vecuronium. Shallow level blockade induced by pancuronium was effectively conducted by Decoopman M, et al. Referenced in "sugammade" wiki article. Pediatric, elderly, cardiac disease, pulmonary disease, and renal disease patients also successfully treated with sugammadex (ESA mtg. June 2007. ASA mtg. October 2007). Concerns of QTc prolongation by sugammadex addressed by de Kam PJ, et al (Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007;107:A1580)The authors concluded sugammadex did not prolong the QT interval based on ICH-E14 guideline criteria.

@@ Line 3: / Line 3: @@
 ==Phase III data==
 Any preliminary phase 3 data available for sharing? [[User:Mdw346|Mdw346]] 15:33, 7 December 2006 (UTC)MDW 07 Dec.06
+Sept 16, 2007:
 Preliminary Phase III and updated Phase II data has been released in Europe June 9-12, 2007 at the European Society of Anaesthesiology Munich, Germany. No surprises- continued successful, effective, dose-dependent fast time to reversal of all levels of neuromuscular blockade induced by rocuronium and vecuronium. Shallow level blockade induced by pancuronium was effectively conducted by Decoopman M, et al. Referenced in "sugammade" wiki article. Pediatric, elderly, cardiac disease, pulmonary disease, and renal disease patients also successfully treated with sugammadex (ESA mtg. June 2007. ASA mtg. October 2007). Concerns of QTc prolongation by sugammadex addressed by de Kam PJ, et al (Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology 2007;107:A1580)The authors concluded sugammadex did not prolong the QT interval based on ICH-E14 guideline criteria.